You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 5,711,931


✉ Email this page to a colleague

« Back to Dashboard


Title: Technetium-99m labelled peptides for imaging inflammation
Abstract:This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to technetium-99m (Tc-99m) labeled leukocyte-binding peptides, methods and kits for making such peptides, and methods for using such peptides to image sites of infection and inflammation in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Buttram; Scott (Derry, NH)
Assignee: Diatide, Inc. (Londonberry, NH)
Filing Date:Jun 07, 1995
Application Number:08/472,535
Claims:1. A reagent for preparing a radiolabeled peptide for imaging sites of intimation within a mammalian body, comprising a specific binding peptide having an amino acid sequence wherein the peptide binds to leukocytes, and a radiolabel-binding moiety selected from the group consisting of moieties of formula

wherein Cp is a protected cysteine and (aa) is any primary .alpha.- or .beta.-amino acid; and a radiolabel binding moiety comprising a single thiol-containing moiety having the formula

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is H, SH or NHR", where R" is H, lower alkyl or --C.dbd.O;

X is SH or NHR", where R" is H, lower alkyl or --C.dbd.O;

R and R' are independently H or lower alkyl;

n is 0, 1 or 2;

and

where B is NHR", where R" is H, lower alkyl or --C.dbd.O, X is SH and n is 1 or 2;

where X is NHR", where R" is H, lower alkyl or --C.dbd.O, B is SH and n is 1 or 2;

where B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH and n is 0 or 1;

and wherein the thiol moiety is in the reduced form;

and wherein the radiolabel-binding moiety is covalently linked to the specific binding peptide.

2. The reagent of claim 1 wherein the specific binding peptide and the Cp(aa)Cp radiolabel binding moiety are covalently linked through one or more amino acids.

3. The reagent of claim 1 wherein the protected cysteine of the Cp(aa)Cp radiolabel binding moiety has a protecting group of the formula

wherein R is a lower alkyl having 1 to 6 carbon atoms, 2-,3-,4-pyridyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

4. The reagent of claim 1 wherein the Cp(aa)Cp radiolabel binding moiety has the formula: ##STR3##

5. The reagent of claim 1 wherein the radiolabel is technetium-99m.

6. The reagent of claim 1 wherein the specific binding peptide is selected from the group consisting of peptides having the formula:

and

7. A kit for preparing a radiopharmaceutical preparation, said kit comprising sealed vial containing a predetermined quantity of the reagent of claim 1 and a sufficient amount of reducing agent to label the peptide with technetium-99m.

8. A reagent according to claim 1 for preparing a radiolabeled peptide for imaging sites of inflammation within a mammalian body, wherein the reagent comprises a specific binding peptide that is comprised of 4 to 100 amino acids and wherein the peptide binds to leukocytes and is covalently linked to a radiolabel-binding moiety.

9. The reagent according to claim 1 wherein the specific binding peptide and the single thiol radiolabel binding moiety are covalently linked through one or more amino acids.

10. The reagent according to claim 1 wherein the radiolabel binding moiety is bound to a radiolabel.

11. The reagent of claim 10 wherein the radiolabel is Tc-99m.

12. A composition of matter comprising the reagent according to claim 8 and a stannous ion.

13. A kit for preparing a radiopharmaceutical preparation, said kit comprising sealed vial containing a predetermined quantity of a reagent according to claim 1 and a sufficient mount of reducing agent to label said reagent with Tc-99m.

14. The reagent according to claim 1 wherein the peptide is chemically synthesized in vitro.

15. The reagent according to claim 14 wherein the peptide is synthesized by solid phase peptide synthesis.

16. The reagent according to claim 14 wherein the radiolabel binding moiety is covalently linked to the peptide during in vitro chemical synthesis.

17. The peptide according to claim 16 wherein the radiolabel binding moiety is covalently linked to the peptide during solid phase peptide synthesis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.